Pharvaris NV (PHVS)
20.59
+0.01
(+0.05%)
USD |
NASDAQ |
May 22, 10:48
Pharvaris Cash from Financing (TTM): 353.20M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 353.20M |
| December 31, 2023 | 352.27M |
| September 30, 2023 | 69.56M |
| June 30, 2023 | 69.28M |
| March 31, 2023 | 9.185M |
| December 31, 2022 | 9.123M |
| September 30, 2022 | 8.737M |
| Date | Value |
|---|---|
| June 30, 2022 | 5.472M |
| March 31, 2022 | -3.659M |
| December 31, 2021 | 169.99M |
| September 30, 2021 | 245.65M |
| June 30, 2021 | 289.49M |
| March 31, 2021 | 289.10M |
| December 31, 2020 | 115.57M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-3.659M
Minimum
Mar 2022
353.20M
Maximum
Mar 2024
141.64M
Average
92.57M
Median
Cash from Financing (TTM) Benchmarks
| uniQure NV | 362.59M |
| ProQR Therapeutics NV | -2.640M |
| Merus NV | 260.02M |
| argenx SE | -- |
| Pharming Group | -0.88M |